InvestSource, Inc.: Zynex Receives Order Increase in July

Aug 07, 2008 (M2 PRESSWIRE via COMTEX) -- ZYXI | Quote | Chart | News | PowerRating -- Stocks in the News: Zynex, Inc. (OTCBB: ZYXI), Ore Pharmaceuticals Inc. (NASDAQ: ORXE), Pressure BioSciences, Inc. (NASDAQ: PBIO), SCOLR Pharma, Inc. (AMEX: DDD)

Aug 05, 2008 -- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 185% for July of 2008 compared to the same month last year. Thomas Sandgaard, CEO, commented, "We are excited to see yet another all-time record for orders in a month, especially since July is traditionally a month where many physicians are taking time off for vacation." Zynex received 2,041 orders in July 2008 versus 715 orders twelve months ago and 1,930 orders in June 2008. Zynex has not yet finalized its results for the third quarter of 2008, including the impact of increased orders. Zynex will state these results in the Form 10-Q for the quarter.

Aug 06, 2008 -- Ore Pharmaceuticals Inc. (NASDAQ: ORXE | Quote | Chart | News | PowerRating) announced today that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for romazarit in metabolic diseases and subsequently observed a lowering of lipids, weight, and glucose levels in in vivo testing. The Company filed recently for patent protection regarding the use of the compound for treatment of metabolic diseases. Ore Pharmaceuticals plans to further develop romazarit, select the most appropriate of the potential indications, and prepare for Phase II clinical trials. The Company will engage in out-licensing efforts in parallel with development efforts. Ore Pharmaceuticals acquired the development rights for romazarit through its partnership with Roche, where it was initially developed as an anti-inflammatory compound and had reached Phase II clinical testing for rheumatoid arthritis. Repositioning efforts at Ore Pharmaceuticals discovered that romazarit modulates a key pathway related to metabolic function. Thomas Barnes, Ph.D., Senior Vice President of Discovery at Ore Pharmaceuticals, said, "Romazarit joins tiapamil and GL1001 as success stories resulting from our indication seeking program. Based on the data derived from our program, we initiated in vivo tests and were pleased to observe decreases in lipid levels, body weight, and plasma glucose in various preclinical models. There are significant opportunities for development in each of these areas." Stephen Donahue, M.D., Senior Vice President of Clinical Development at Ore Pharmaceuticals, said, "Romazarit has exhibited potential for treating dyslipidemia and other highly prevalent metabolic conditions such as obesity. The compound was well tolerated in clinical testing, and has been well characterized by Roche in prior studies."

Aug 06, 2008 -- Pressure BioSciences, Inc. (NASDAQ: PBIO | Quote | Chart | News | PowerRating) today announced the market release of its pressure cycling technology-enhanced trypsin digestion application for proteomics, a major new addition to its PCT family of products. Named "Proteolysis (Trypsin)-PrEP", this new PCT-enhanced processing application was unveiled at the Drug Discovery & Development of Innovative Therapeutics Expo 2008, being held this week at the World Trade Center Boston & Seaport Hotel, in Boston, Massachusetts. Dr. Alexander Lazarev, Vice President of Research and Development for PBI, said: "Over the past two months, three independent research laboratories using pressure cycling technology have published findings indicating that PCT can reduce the incubation time required for the trypsin digestion of proteins from hours to minutes, and often with a concomitant improvement in the quality of the results of the digestion process. We have replicated these results in our own laboratory. This is a highly significant finding because we believe that the acceleration of protein digestion by PCT, together with the potential for an improvement in the quality of the result, will offer the many researchers currently using mass spectrometry the ability to complete their experiments significantly faster and with the potential for better quality than at the present time. We believe that this may lead to accelerated discoveries and quicker time for new products to get to market." Richard T. Schumacher, Founder, President, and CEO of PBI commented: "The preparation of samples by trypsin digestion prior to mass spectrometry analysis is a new market for our Company. This market is very large and is growing at a robust rate. We have seen a significant increase in the number of inquiries about PCT, and in requests for demonstrations of the technology, since the publication and presentation of these exciting discoveries two months ago. We believe that this increased interest in PCT will manifest itself in increased installations of the PCT Sample Preparation System during the second half of 2008, as compared to the first two quarters of the year. This is a very exciting time for all stakeholders of PBI."

Aug 06, 2008 -- SCOLR Pharma, Inc. (AMEX: DDD | Quote | Chart | News | PowerRating) announced today that it has submitted to the Food and Drug Administration an Abbreviated New Drug Application (ANDA) for a 120 milligram 12-hour pseudoephedrine tablet based on the Company's patented Controlled Delivery Technology (CDT ) platform. This is the first application submitted by SCOLR based on its CDT platform. Stephen J. Turner, SCOLR's Vice President and Chief Technical Officer, stated, "We believe the primary advantages our formulation may have over currently marketed pseudoephedrine tablets relates to the overall efficiency of the formulation. We were able to demonstrate bio-equivalence for our product while significantly reducing the overall tablet size, gaining important manufacturing margin advantages over currently available tablets. Since pseudoephedrine tablets now face marketing pressure because of required placement behind the counter in the pharmacy, we believe that margin and size may play an important role in the selection process for consumers, and could give SCOLR an advantage in the competitive store-brands and private label marketplace." The Company expects to complete the ibuprofen trial late this year. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States.

Market Wrap for August 6th, 2008

The S&P 500 eked out a slight gain on Wednesday. Still, stock market bulls are pleased with the end result, considering the market was able to climb out of negative territory, and the gain comes after the previous session's rally of nearly 3%. A strong showing by large-cap tech helped offset negative news out of the financial sector. Crude prices dropped for the third consecutive session, which also helped bring buyers to the table.

The S&P 500 settled with a gain of 0.3% after being down as much as 0.7%. Six of the ten economic sectors advanced. The Nasdaq Composite handily outperformed with a gain of 1.2%, partially due to better-than-expected earnings from a network and communication device giant. With regard to crude oil, prices fell 0.7% to $118.37 per barrel after traders digested the government's weekly energy inventory data that painted a picture of mixed demand. Crude stockpiles unexpectedly rose, although gasoline inventory levels dropped by a large amount. After some volatile action, oil prices dropped from a gain of 1.1%, which coincided with the stock market's recovery from its session low. Crude prices are down 5.4% this week. The tech sector was the leader behind the market's recovery, ending the day with a gain of 1.3%. Cisco (CSCO 23.96, +1.31) reported second quarter earnings that modestly topped expectations on the top and bottom line. The company issued revenue guidance for the next two quarters that was slightly below consensus, but reiterated its long-term growth rate guidance of 12% to 17%. Microsoft (MSFT 27.01, +0.80) also provided leadership, with shares rising 3% after a UBS analyst said Microsoft will buy back as much as $20 billion shares, according to Bloomberg.com. Strikingly, the energy sector (+1.9%) posted the largest advance this session, despite the drop in crude prices. The financial sector (-1.0%) settled well above its session low when it was down 2.4%, but still acted as a drag on the broader market. The telecom sector (-1.4%) posted the largest decline.

ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO TO: www.investsourceinc.com.

To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to www.ceo-corner.com This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation to buy or sell securities. InvestSource, Inc. has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by InvestSource, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this release have not given an opinion or approved the statements made in this release.

InvestSource, Inc. is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. InvestSource, Inc. affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. InvestSource, Inc. will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market. Please consult your broker before purchasing or selling any securities mentioned herein. To view full disclaimers, please go to http://investsourceinc.com/php/disclaimer.php (disclaimers).

CONTACT: InvestSource, Inc e-mail: info@investsourceinc.com WWW: http://www.investsourceinc.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index